Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial
Carregando...
Citações na Scopus
33
Tipo de produção
article
Data de publicação
2019
Editora
AMER MEDICAL ASSOC
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
BURTNESS, Barbara
HADDAD, Robert
DINIS, Jose
TRIGO, Jose
YOKOTA, Tomoya
VIANA, Luciano de Souza
ROMANOV, Ilya
VERMORKEN, Jan
BOURHIS, Jean
TAHARA, Makoto
Autor de Grupo de pesquisa
LUX-HEAD & Neck 2 Investigators
Editores
Coordenadores
Organizadores
Citação
JAMA ONCOLOGY, v.5, n.8, p.1170-1180, 2019
Resumo
ImportanceLocoregionally advanced head and neck squamous cell cancer (HNSCC) is treated curatively; however, risk of recurrence remains high among some patients. The ERBB family blocker afatinib has shown efficacy in recurrent or metastatic HNSCC. ObjectiveTo assess whether afatinib therapy after definitive chemoradiotherapy (CRT) improves disease-free survival (DFS) in patients with HNSCC. Design, Setting, and ParticipantsThis multicenter, phase 3, double-blind randomized clinical trial (LUX-Head & Neck 2) studied 617 patients from November 2, 2011, to July 4, 2016. Patients who had complete response after CRT, comprising radiotherapy with cisplatin or carboplatin, with or without resection of residual disease, for locoregionally advanced high- or intermediate-risk HNSCC of the oral cavity, hypopharynx, larynx, or oropharynx were included in the study. Data analysis was of the intention-to-treat population. InterventionsPatients were randomized (2:1) to treatment with afatinib (40 mg/d) or placebo, stratified by nodal status (N0-2a or N2b-3) and Eastern Cooperative Oncology Group performance status (0 or 1). Treatment continued for 18 months or until disease recurrence, unacceptable adverse events, or patient withdrawal. Main Outcomes and MeasuresThe primary end point was DFS, defined as time from the date of randomization to the date of tumor recurrence or secondary primary tumor or death from any cause. Secondary end points were DFS at 2 years, overall survival (defined as time from the date of randomization to death), and health-related quality of life. ResultsA total of 617 patients were studied (mean [SD] age, 58 [8.4] years; 528 male [85.6%]). Recruitment was stopped after a preplanned interim futility analysis on July 4, 2016, on recommendation from an independent data monitoring committee. Treatment was discontinued. Median DFS was 43.4 months (95% CI, 37.4 months to not estimable) in the afatinib group and not estimable (95% CI, 40.1 months to not estimable) in the placebo group (hazard ratio, 1.13; 95% CI, 0.81-1.57; stratified log-rank test P=.48). The most common grade 3 and 4 drug-related adverse effects were acneiform rash (61 [14.8%] of 411 patients in the afatinib group vs 1 [0.5%] of 206 patients in the placebo group), stomatitis (55 [13.4%] in the afatinib group vs 1 [0.5%] in the placebo group), and diarrhea (32 [7.8%] in the afatinib group vs 1 [0.5%] in the placebo group). Conclusions and RelevanceThis study's findings indicate that treatment with afatinib after CRT did not improve DFS and was associated with more adverse events than placebo in patients with primary, unresected, clinically high- to intermediate-risk HNSCC. The use of adjuvant afatinib after CRT is not recommended. Trial RegistrationClinicalTrials.gov identifier: NCT01345669
Palavras-chave
Referências
- Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217
- Ang KK, 2002, CANCER RES, V62, P7350
- Argiris A, 2010, J CLIN ONCOL, V28, P5294, DOI 10.1200/JCO.2010.30.6423
- Bauman JE, 2013, BRIT J CANCER, V109, P2096, DOI 10.1038/bjc.2013.576
- Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422
- Burtness B, 2005, J CLIN ONCOL, V23, P8646, DOI 10.1200/JCO.2005.02.4646
- Cancer Therapy Evaluation Program, 2006, CANC THER EV PROGR C
- Chen C, 2007, J CLIN ONCOL, V25, P4880, DOI 10.1200/JCO.2007.12.9650
- Cohen EEW, 2017, ANN ONCOL, V28, P2526, DOI 10.1093/annonc/mdx344
- Cohen EEW, 2014, J CLIN ONCOL, V32, P2735, DOI 10.1200/JCO.2013.54.6309
- Deng ZY, 2014, INT J ONCOL, V45, P67, DOI 10.3892/ijo.2014.2440
- Fayers PM, 2001, EORTC QLQ C30 SCORIN
- Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
- Haddad R, 2013, LANCET ONCOL, V14, P257, DOI 10.1016/S1470-2045(13)70011-1
- Harrington K, 2015, J CLIN ONCOL, V33, P4202, DOI 10.1200/JCO.2015.61.4370
- Kelly JR, 2017, JAMA ONCOL, V3, P1107, DOI 10.1001/jamaoncol.2016.5769
- Lango MN, 2009, HEAD NECK-J SCI SPEC, V31, P328, DOI 10.1002/hed.20976
- Lee S, 2015, P NATL ACAD SCI USA, V112, P13225, DOI 10.1073/pnas.1518361112
- Leonard B, 2018, CANCER RES, V78, P4331, DOI 10.1158/0008-5472.CAN-18-0459
- Machiels JPH, 2015, LANCET ONCOL, V16, P583, DOI 10.1016/S1470-2045(15)70124-5
- Mesia R, 2015, LANCET ONCOL, V16, P208, DOI 10.1016/S1470-2045(14)71198-2
- Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139
- Redlich N, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0029-0
- Seiwert TY, 2007, NAT CLIN PRACT ONCOL, V4, P156, DOI 10.1038/ncponc0750
- Stewart JSW, 2009, J CLIN ONCOL, V27, P1864, DOI 10.1200/JCO.2008.17.0530
- Vermorken JB, 2014, ANN ONCOL, V25, P801, DOI 10.1093/annonc/mdt574
- Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656
- Wang DS, 2017, CLIN CANCER RES, V23, P677, DOI 10.1158/1078-0432.CCR-16-0558
- Weinberger PM, 2006, J CLIN ONCOL, V24, P736, DOI 10.1200/JCO.2004.00.3335
- World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053